FOXP3 and inflammatory bowel disease: EZH2 has shown decreased expression in patients with IBD (Figure 2) [5], and the loss of EZH2-FoxP3 interaction in Tregs is thought to compromise Treg physiology and intestinal inflammation, which can remain chronically activated [48].